Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

EQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference 


EQS-News: MorphoSys AG / Key word(s): Conference
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference 

08.01.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Media Release

Planegg/Munich, Germany, January 8, 2024

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference 

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. PST in San Francisco, California. The company’s Chief Financial Officer, Lucinda Crabtree, Ph.D., and Chief Research and Development Officer, Tim Demuth, M.D., Ph.D., will also be in attendance and available to address questions. 

A live webcast of the presentation can be accessed on the Investors section of MorphoSys’ website at https://www.morphosys.com/en/investors. An archived version of the webcast will be available on the company’s website following the presentation.

About MorphoSys
At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter at X and LinkedIn.

For more information, please contact:

Media Contacts:
Thomas Biegi
Senior Vice President, Corporate Affairs
Tel: +49 (0)151 / 74612318
[email protected]
Investor Contact:
Dr. Julia Neugebauer
Vice President, Global Investor Relations
Tel: +49 (0)89 / 899 27 179
[email protected]

Eamonn Nolan
Director, Corporate Communications Investor Relations
Tel: +1 617-548-9271
[email protected]
 


08.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: investors@morphosys.com
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 1809537

 
End of News EQS News Service

1809537  08.01.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1809537&application_name=news&site_id=sharewise

MorphoSys AG Stock

€66.75
-0.150%
The price for the MorphoSys AG stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.150%).
With 7 Buy predictions and not the single Sell prediction the community is currently very high on MorphoSys AG.
On the other hand, the target price of 65 € is below the current price of 66.75 € for MorphoSys AG, so the potential is actually -2.62%.
Like: 0
Share
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments